Inventages Venture Capital Investment

Ripple Foods specializes in producing high-quality, dairy-free milk alternatives that prioritize nutrition and taste. Their products are designed to be high in protein, offering eight times the protein found in almond milk while containing half the sugar of traditional dairy milk. Additionally, Ripple's beverages are rich in bioavailable calcium, providing 50% more than regular milk, and are a good source of potassium and omega-3 fatty acids. With a focus on delivering a creamy texture that enhances the drinking experience, Ripple aims to provide a satisfying alternative for those seeking non-dairy options without sacrificing flavor or nutritional value.

Accera, Inc. is a clinical stage biotechnology company focused on developing therapies for central nervous system disorders, particularly neurodegenerative diseases such as Alzheimer's and Parkinson's. Established in 2001 and headquartered in Broomfield, Colorado, Accera leverages a proprietary scientific platform to address significant unmet medical needs in brain health. The company is advancing its product pipeline, including Ketasyn, a therapeutic molecule designed to support cognitive function in patients with age-associated memory impairment. Accera operates as a subsidiary of Nestlé S.A.

XOLUTION GmbH is a Munich-based company that specializes in the manufacture of re-closable ends for beverage cans. The company has developed the XO resealable can, which has garnered recognition for its innovative design, winning a Silver Award in the Prototype category at the Can of the Year Awards in Dubai in 2009. The product has undergone extensive market research and field testing, positioning XOLUTION as a potential leader in the beverage packaging industry. Under the leadership of Chief Executive Marc von Rettberg and Vice President of R&D Christian Bratsch, the company has established product design guidelines focused on ease of use for consumers, seamless integration for beverage fillers, and improved branding options for beverage brands, all at a reasonable cost. XOLUTION's rapid prototyping and testing capabilities, developed at their Salzburg R&D Center, further enhance their competitive edge. The company is dedicated to converting innovative concepts into technologically advanced products that will significantly impact the canned beverage market.

Cognoptix, Inc. is a healthcare company based in Marlborough, Massachusetts, focused on the early detection and diagnosis of Alzheimer's disease through a non-invasive eye scanning test. The company has developed the SAPPHIRE II, a clinical device that allows for in-office examinations by clinicians. This innovative technology utilizes a fluorescent ligand eye scanning technique, where a beta amyloid-specific compound is applied to the eye and then analyzed by the SAPPHIRE II instrument. By measuring amyloid aggregates in the eye's lens, Cognoptix aims to provide a quick, reliable, and cost-effective method for early diagnosis, ultimately enabling timely treatment for patients. Founded in 2001, Cognoptix was previously known as Neuroptix Corporation before rebranding in 2012.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Phagenesis Limited is focused on developing medical device technology aimed at treating dysphagia, a condition that impairs swallowing, often resulting from strokes or brain injuries. The company's primary product, Phagenyx, consists of a base station that delivers electrical stimulations to the patient and records pertinent information, along with a catheter that is introduced through the nose to stimulate the pharynx. This innovative approach leverages the brain's ability to relearn lost functions through neuroplasticity, effectively aiding patients in regaining control over their swallowing mechanisms. Founded in 2007 and based in Manchester, United Kingdom, Phagenesis emphasizes research and evidence-based solutions, with foundational work led by Professor Shaheen Hamdy of the University of Manchester, whose findings have been published in prestigious medical journals.

Phosphate Therapeutics is an independent specialty pharmaceutical company based in the UK, dedicated to developing mineral-derived hospital pharmaceuticals. The company is currently focused on advancing its phosphate binder, PT20, which is designed to treat hyperphosphataemia, a condition characterized by elevated phosphate levels in the blood, often associated with chronic kidney disease (CKD). PT20 is intended for use in patients with both dialysis-dependent and dialysis-independent forms of CKD. The company aims to utilize its resources to complete the Phase 2 development of this drug, having acquired global rights from the Medical Research Council. Through its innovative approach, Phosphate Therapeutics seeks to address the critical need for effective treatments in patients suffering from systemic phosphate accumulation related to late-stage renal disease.

Phagenesis Limited is focused on developing medical device technology aimed at treating dysphagia, a condition that impairs swallowing, often resulting from strokes or brain injuries. The company's primary product, Phagenyx, consists of a base station that delivers electrical stimulations to the patient and records pertinent information, along with a catheter that is introduced through the nose to stimulate the pharynx. This innovative approach leverages the brain's ability to relearn lost functions through neuroplasticity, effectively aiding patients in regaining control over their swallowing mechanisms. Founded in 2007 and based in Manchester, United Kingdom, Phagenesis emphasizes research and evidence-based solutions, with foundational work led by Professor Shaheen Hamdy of the University of Manchester, whose findings have been published in prestigious medical journals.

MSI Methylation Sciences, Inc. is a biotechnology company based in Canada that focuses on developing oral and small molecule therapies for the adjunctive treatment of Major Depressive Disorder (MDD). Founded in 2007, the company is known for its product Strada, an orally administered therapy designed to alleviate symptoms of depression in MDD patients. Additionally, MSI develops S-Adenosyl Methionine, a prescription drug that serves as a dietary supplement. The company aims to reduce drug development risk while providing effective treatment options based on ademetionine, a naturally occurring molecule crucial for various biochemical processes in the body.

Shield Therapeutics is an independent specialty pharmaceutical company based in Wollerau, Switzerland, concentrating on the development and commercialization of late-stage, mineral-derived pharmaceuticals aimed at addressing significant unmet medical needs. The company’s primary focus is on its lead product, Feraccru, which is designed for the treatment of iron deficiency anemia associated with inflammatory bowel disease, as well as chronic kidney disease. Additionally, Shield Therapeutics is advancing PT20, a product intended for the management of hyperphosphatemia, which is nearing the final stages of development. The company generates most of its revenue from the Feraccru segment.

Accera, Inc. is a clinical stage biotechnology company focused on developing therapies for central nervous system disorders, particularly neurodegenerative diseases such as Alzheimer's and Parkinson's. Established in 2001 and headquartered in Broomfield, Colorado, Accera leverages a proprietary scientific platform to address significant unmet medical needs in brain health. The company is advancing its product pipeline, including Ketasyn, a therapeutic molecule designed to support cognitive function in patients with age-associated memory impairment. Accera operates as a subsidiary of Nestlé S.A.

CMP Therapeutics, Ltd. is a biopharmaceutical company based in Bicester, United Kingdom, specializing in the development of chitin microparticles for targeting macrophages and dendritic cells in the nasal and respiratory tract. Founded in 2004, the company focuses on creating a nasal spray designed to treat allergic rhinitis and enhance natural resistance to influenza and other respiratory pathogens. Additionally, CMP Therapeutics' chitin microparticles serve as an adjuvant in nasal vaccines, providing a means for patients to prevent and treat allergy-related conditions, asthma, and other infectious diseases through intranasal delivery systems or functional foods.

Tanfield Direct is an online provider of natural foods.

MooBella has developed a revolutionary, disruptive technology that has the potential to transform and expand the nearly $60 billion ice cream industry. It enables instantaneous aeration, flavoring and freezing of ice cream into scoops of premium hard ice cream within seconds, and thereby eliminating the frozen supply chain.

Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.

Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.

Accera, Inc. is a clinical stage biotechnology company focused on developing therapies for central nervous system disorders, particularly neurodegenerative diseases such as Alzheimer's and Parkinson's. Established in 2001 and headquartered in Broomfield, Colorado, Accera leverages a proprietary scientific platform to address significant unmet medical needs in brain health. The company is advancing its product pipeline, including Ketasyn, a therapeutic molecule designed to support cognitive function in patients with age-associated memory impairment. Accera operates as a subsidiary of Nestlé S.A.

Cognoptix, Inc. is a healthcare company based in Marlborough, Massachusetts, focused on the early detection and diagnosis of Alzheimer's disease through a non-invasive eye scanning test. The company has developed the SAPPHIRE II, a clinical device that allows for in-office examinations by clinicians. This innovative technology utilizes a fluorescent ligand eye scanning technique, where a beta amyloid-specific compound is applied to the eye and then analyzed by the SAPPHIRE II instrument. By measuring amyloid aggregates in the eye's lens, Cognoptix aims to provide a quick, reliable, and cost-effective method for early diagnosis, ultimately enabling timely treatment for patients. Founded in 2001, Cognoptix was previously known as Neuroptix Corporation before rebranding in 2012.

Steaz is a brand of organic green tea beverages made with ingredients you can feel good about. Since 2002, Steaz has provided fans with healthy, high-quality beverages while maintaining strong, socially responsible relationships with the company’s ingredient partners around the world. Their pride is anchored in their organic certification and dedication to fair trade and support for sustainable farming around the world. Steaz is available in three healthy and delicious product lines – iced green teas, energy drinks and cactus water beverages. Find your flavor and start sipping on certified goodness.

GC-Rise Pharmaceutical Co., Ltd. is a foreign-owned enterprise invested by INVENTAGES, a prominent European investment group in the healthcare sector. The company is dedicated to improving human healthcare and enhancing quality of life. It leverages strategic partnerships across America, Europe, and Japan, utilizing their extensive experience in clinical development, trials, and regulatory processes in China. GC-Rise specializes in healthcare services focused on gynecology, obstetrics, and pediatrics, aiming to provide innovative, safe, and highly efficient medical products and treatment solutions for women and children. Through its comprehensive approach, the company seeks to ensure that patients have access to the necessary healthcare services and products to maintain their health.

Food Quality Sensor International, Inc. is a sensor technology company based in Lexington, Massachusetts, founded in 2004. It specializes in the development and commercialization of real-time and interactive devices for measuring food freshness. The company's primary products include SensorQ, which assesses the freshness of meat and poultry within their packaging, and SensorfreshQ, a handheld device that identifies spoilage in these products. Food Quality Sensor International serves a variety of markets, including food processing, grocery distribution, food service, regulatory bodies, defense, and consumer retail.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

MooBella has developed a revolutionary, disruptive technology that has the potential to transform and expand the nearly $60 billion ice cream industry. It enables instantaneous aeration, flavoring and freezing of ice cream into scoops of premium hard ice cream within seconds, and thereby eliminating the frozen supply chain.

Phytomedics is committed to quality, technological innovation and research. Their powerful portfolio of overlapping proprietary technologies is targeted to turning green plants into reliable vehicles for discovering and manufacturing proprietary botanical pharmaceuticals and nutraceuticals. NewLeadTM and RhizexTM elicitation and optimization processes greatly enhance the efficacy and reproducibility of plant-derived products and increase the synergy between various chemical components of plant extracts. The Company has developed an efficient and proprietary discovery and lead prioritization process based on high-power bio-informatics, high-tech data mining, efficient activity screening, and an extensive network of international collaborations.

DiObex, Inc. operates as a biotechnology company in the United States. The company develops novel products for the treatment of metabolic disorders, including type-one and type-two diabetes, dyslipidemia, obesity, and diabetic nephropathy. Its products include DIO-901, a very low dose glucagon product that is developed for the reduction of nocturnal hypoglycemia in patients with type-one diabetes; and DIO-902, a cortisol synthesis inhibitor that is developed as a therapy for glucose and cholesterol control in patients with type-two diabetes. DiObex, Inc. was founded in 2003 and is based in San Francisco, California.

Cryolog S.A., founded in 2002 and headquartered in Nantes, France, specializes in cold chain management solutions for fresh and ultra-fresh food products. The company develops time-temperature integrators (TTIs) in the form of self-adhesive labels, which serve as biological tracers using food-grade microorganisms. One of its key products, TOPCRYO, is a thermosensitive microbiological tool that visually indicates the impact of time and temperature on food conservation through a color change from green to red. This innovative product allows users to quickly assess the freshness and safety of food items throughout their lifecycle, thereby enhancing decision-making in the cold chain food industry. Cryolog was taken over in 2014 by CLOCK-T ° and is primarily supported by CapAgro, an investment fund focused on agribusiness innovation.

Honest Tea is an organic bottled tea company based in the United States, co-founded by Seth Goldman and Barry Nalebuff in 1998. The company emerged from a desire to create a beverage that is less sweet yet flavorful, filling a gap in the market for healthier drink options. Honest Tea offers a diverse range of tea products, including black, green, white, and herbal varieties, which are distributed through a network of food stores and distributors. The brand emphasizes all-natural ingredients and aims to foster honest relationships with its customers, suppliers, and the environment. Since its inception, Honest Tea has experienced significant growth and is now available in over 100,000 stores across the country. Following an initial investment from The Coca-Cola Company in 2008, Honest Tea was fully acquired in 2011, but continues to operate as an independent business unit. Under Goldman’s leadership as President and TeaEO, the company maintains its commitment to health, environmental sustainability, and social responsibility.

CMP Therapeutics, Ltd. is a biopharmaceutical company based in Bicester, United Kingdom, specializing in the development of chitin microparticles for targeting macrophages and dendritic cells in the nasal and respiratory tract. Founded in 2004, the company focuses on creating a nasal spray designed to treat allergic rhinitis and enhance natural resistance to influenza and other respiratory pathogens. Additionally, CMP Therapeutics' chitin microparticles serve as an adjuvant in nasal vaccines, providing a means for patients to prevent and treat allergy-related conditions, asthma, and other infectious diseases through intranasal delivery systems or functional foods.

Accera, Inc. is a clinical stage biotechnology company focused on developing therapies for central nervous system disorders, particularly neurodegenerative diseases such as Alzheimer's and Parkinson's. Established in 2001 and headquartered in Broomfield, Colorado, Accera leverages a proprietary scientific platform to address significant unmet medical needs in brain health. The company is advancing its product pipeline, including Ketasyn, a therapeutic molecule designed to support cognitive function in patients with age-associated memory impairment. Accera operates as a subsidiary of Nestlé S.A.

Technologie BiolActis (BiolActis) is a Canadian biotechnology company incorporated in 1998. Since its foundation, the entrepreneurs were committed to create novel Biologics meeting well identified needs from the Wellness Industries (Functional Nutrition, Dietary Supplements, Cosmeceuticals and Pharmaceuticals).

TriMed Research, Inc. engages in the research and development of therapeutic products primarily related to mammary gland protein designated as MAA.

DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).

Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.

The Cavis microcaps has many years’ experience in the field of alginate-based encapsulation and immobilisation. The main focus of their services is encapsulation of additives for the food industry and pet food sectors. Their products are used in food technology as well as in cosmetic and technical applications.

Cryolog S.A., founded in 2002 and headquartered in Nantes, France, specializes in cold chain management solutions for fresh and ultra-fresh food products. The company develops time-temperature integrators (TTIs) in the form of self-adhesive labels, which serve as biological tracers using food-grade microorganisms. One of its key products, TOPCRYO, is a thermosensitive microbiological tool that visually indicates the impact of time and temperature on food conservation through a color change from green to red. This innovative product allows users to quickly assess the freshness and safety of food items throughout their lifecycle, thereby enhancing decision-making in the cold chain food industry. Cryolog was taken over in 2014 by CLOCK-T ° and is primarily supported by CapAgro, an investment fund focused on agribusiness innovation.

SelectX Pharmaceuticals, Inc. is a biopharmaceutical company based in Boston, Massachusetts, specializing in the discovery and development of aminoglycoside therapeutics to address unmet medical needs. The company is advancing its lead candidate, SXP2523, a next-generation aminoglycoside antibiotic aimed at treating drug-resistant gram-negative infections acquired in hospital settings. Additionally, SelectX is developing an inhaled aminoglycoside antibiotic intended for patients with Cystic Fibrosis and other respiratory diseases who face similar drug resistance challenges. Beyond antibiotics, the company is also focused on identifying and optimizing non-antibiotic aminoglycoside leads to target critical biological pathways, including cell migration and the correction of nonsense mutations. SelectX Pharmaceuticals was originally known as OmniScience Pharmaceuticals Inc. before rebranding in September 2002.

Phytomedics is committed to quality, technological innovation and research. Their powerful portfolio of overlapping proprietary technologies is targeted to turning green plants into reliable vehicles for discovering and manufacturing proprietary botanical pharmaceuticals and nutraceuticals. NewLeadTM and RhizexTM elicitation and optimization processes greatly enhance the efficacy and reproducibility of plant-derived products and increase the synergy between various chemical components of plant extracts. The Company has developed an efficient and proprietary discovery and lead prioritization process based on high-power bio-informatics, high-tech data mining, efficient activity screening, and an extensive network of international collaborations.